Design and analysis of pilot studies: recommendations for good practice, J Eval Clin Pract, vol.10, pp.307-312, 2004. ,

The design and interpretation of pilot trials in clinical research in critical care, Crit Care Med, vol.37, pp.69-74, 2009. ,

What is a pilot or feasibility study? A review of current practice and editorial policy, BMC Med Res Methodol, vol.10, p.67, 2010. ,

A tutorial on pilot studies: the what, why and how, BMC Med Res Methodol, vol.10, p.1, 2010. ,

Clinical trials: a practical approach, 1983. ,

Sample sizes for clinical trials, 2008. ,

, Guideline on clinical trials in small populations, European Medicines Agency CHMP/EWP/83561/2005, p.29, 2006.

, Concept paper on extrapolation of efficacy and safety in medicine development, European Medicines Agency EMA, 2012.

Small clinical trials: issues and challenges, p.29, 2001. ,

Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper, Ann Oncol, vol.26, issue.2, pp.300-306, 2015. ,

Optimal statistical decisions, 1970. ,

Applied statistical decision theory, 1977. ,

Decision analysis: a Bayesian approach, 1988. ,

The choice of sample size, J Royal Stat Soc: Ser D (The Statistician), vol.46, pp.129-138, 1997. ,

A gridding method for Bayesian sequential decision problems, J Computat Graphic Statist, vol.12, pp.566-584, 2003. ,

Hybrid methods for calculating optimal few-stage sequential strategies: Data monitoring for a clinical trial, Stat Comput, vol.12, pp.147-152, 2002. ,

Adaptive two-stage designs in phase II clinical trials, Stat Med, vol.25, pp.3382-3395, 2006. ,

Sample sizes for phase II clinical trials derived from Bayesian decision theory, Stat Med, vol.13, pp.2493-2502, 1994. ,

Optimal cost-effective designs of phase II proof of concept trials and associated go-no go decisions, J Biopharm Stat, vol.19, pp.424-436, 2009. ,

Evaluation of early efficacy endpoints for proof-of-concept trials, J Biopharm Stat, vol.23, pp.413-424, 2013. ,

Adaptive group sequential design for phase II clinical trials: A Bayesian decision theoretic approach, Stat Med, vol.28, pp.3347-3362, 2009. ,

Bayesian optimal design for phase II screening trials, Biometrics, vol.64, pp.886-894, 2008. ,

Designing a series of decisiontheoretic phase II trials in a small population, Stat Med, vol.31, pp.4337-4351, 2012. ,

Admissible two-stage designs for phase II cancer clinical trials, Stat Med, vol.23, pp.561-569, 2004. ,

Adaptation in clinical development plans and adaptive clinical trial designs, Statist Interf, vol.5, pp.431-442, 2012. ,

The rheumatoid arthritis drug development model: A case study in Bayesian clinical trial simulation, Pharm Stat, vol.8, pp.371-389, 2009. ,

A decision analytic approach to a futility analysis of a phase II pharmaceutical study, J Biopharm Stat, vol.11, pp.209-225, 2001. ,

A comparative phase II clinical trials procedure for choosing the best of three treatments, Stat Med, vol.10, pp.1327-1340, 1991. ,

Screening designs for drug development, Biostatistics, vol.8, pp.595-608, 2007. ,

Approximately optimal designs for phase II clinical studies, J Biopharm Stat, vol.8, pp.469-487, 1998. ,

Sample size determination for phase II clinical trials based on Bayesian decision theory, Biometrics, vol.54, pp.279-294, 1998. ,

Decision-theoretic designs for phase II clinical trials allowing for competing studies, Biometrics, vol.59, pp.402-409, 2003. ,

Optimal sample sizes for phase II clinical trials and pilot studies, Stat Med, vol.31, pp.1031-1042, 2012. ,

Optimal choice of the number of treatments to be included in a clinical trial, Stat Med, vol.28, pp.1321-1338, 2009. ,

Decision-theoretic designs for pre-phase II screening trials in oncology, Biometrics, vol.57, pp.1089-1095, 2001. ,

Decision theoretic designs for phase II clinical trials with multiple outcomes, Biometrics, vol.55, pp.971-977, 1999. ,

A decision theory approach to phase II clinical trials, Biomedicine, vol.26, pp.262-266, 1977. ,

A Bayesian approach to the design of phase II clinical trials, Biometrics, vol.44, pp.823-836, 1988. ,

Design of phase II clinical trials in cancer using decision theory, Cancer Treat Rep, vol.64, pp.519-524, 1980. ,

Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes, Biometrics, vol.69, pp.673-682, 2013. ,

Bayesian enrichment strategies for randomized discontinuation trials, Biometrics, vol.68, pp.203-211, 2012. ,

Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint, Stat Med, vol.31, pp.1804-1820, 2012. ,

Bayesian decision sequential analysis with survival endpoint in phase II clinical trials, Stat Med, vol.28, pp.1339-1352, 2009. ,

One-sided sequential stopping boundaries for clinical trials: A decision-theoretic approach, Biometrics, vol.44, pp.219-227, 1988. ,

Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods, Clin Trials, vol.10, pp.54-62, 2013. ,

Optimal adaptive randomized designs for clinical trials, Biometrika, vol.94, pp.673-687, 2007. ,

Bayesian adaptive designs for clinical trials, Biometrika, vol.92, pp.633-646, 2005. ,

An efficient sequential design of clinical trials, J Stat Plan Inference, vol.143, pp.283-295, 2013. ,

Choosing sample size for a clinical trial using decision analysis, Biometrika, vol.90, pp.923-936, 2003. ,

Sequential medical trials involving paired data, Biometrika, vol.68, pp.119-132, 1981. ,

An economic approach to clinical trial design and research priority-setting, Health Econ, vol.5, pp.513-524, 1996. ,

A dynamic programming approach to the efficient design of clinical trials, J Health Econ, vol.20, pp.797-822, 2001. ,

Expected value of information and decision making in HTA, Health Econ, vol.16, pp.195-209, 2007. ,

How large should a clinical trial be?, J Royal Stati Soc: Ser D (The Statistician), vol.49, pp.177-187, 2000. ,

A behavioral Bayes method for determining the size of a clinical trial, Drug Inf J, vol.34, pp.355-363, 2000. ,

A decision theoretic approach to sample size determination in clinical trials, J Biopharm Stat, vol.12, pp.535-551, 2002. ,

The sample size for a clinical trial: A Bayesian-decision theoretic approach, Stat Med, vol.20, pp.841-858, 2001. ,

A decisiontheoretic evaluation of early stopping rules, Stat Med, vol.11, pp.673-683, 1992. ,

The cost-benefit of a randomized trial to a health care organization, Control Clin Trials, vol.19, pp.198-211, 1998. ,

Interim monitoring of clinical trials: Decision theory, dynamic programming and optimal stopping, Kuwait J Sci, vol.40, pp.43-59, 2013. ,

A Bayesian decisiontheoretic sequential response-adaptive randomization design, Stat Med, vol.32, pp.1975-1994, 2013. ,

A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety, Stat Med, vol.28, pp.2293-2306, 2009. ,

A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy nd safety: Imbalanced sample size in treatment groups, Stat Methods Med Res, vol.20, pp.389-400, 2011. ,

A Bayesian costbenefit approach to the determination of sample size in clinical trials, Stat Med, vol.27, pp.68-82, 2008. ,

Group sequential clinical trials: A classical evaluation of Bayesian decision-theoretic designs, J Am Stat Assoc, vol.89, pp.1528-1534, 1994. ,

Bayesian decisiontheoretic group sequential clinical trial design based on a quadratic loss function: A frequentist evaluation, Clin Trial, vol.4, pp.5-14, 2007. ,

An optimization approach to calculating sample sizes with binary responses, J Biopharm Stat, vol.24, pp.715-731, 2014. ,

Adaptive, group sequential and decision theoretic approaches to sample size determination, Stat Med, vol.25, pp.3250-3269, 2006. ,

Bayesian sequential analysis for multiple-arm clinical trials, Stat Comput, vol.19, pp.99-109, 2009. ,

A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs, Stat Med, vol.26, pp.4976-4988, 2007. ,

A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk, Stat Med, vol.32, pp.1763-1777, 2013. ,

A fully Bayesian approach to calculating sample sizes for clinical trials with binary responses, Drug Inf J, vol.36, pp.143-150, 2002. ,

The choice of sample size: A mixed Bayesian/frequentist approach, Stat Meth Med Res, vol.18, pp.183-194, 2009. ,

Bayesian sample size calculation for estimation of the difference between two binomial proportions, Stat Meth Med Res, vol.22, pp.598-611, 2013. ,

Gittins indices and constrained allocation in clinical trials, Biometrika, vol.78, pp.101-111, 1991. ,

Implementation of backward induction for sequentially adaptive clinical trials, J Computat Graphic Stat, vol.15, pp.398-413, 2006. ,

Bayesian adaptive model selection for optimizing group sequential clinical trials, Stat Med, vol.27, pp.5586-5604, 2008. ,

Optimal sample size determinations from an industry perspective based on the expected value of information, Clin Trial, vol.5, pp.587-594, 2008. ,

Optimal clinical trial design using value of information methods with imperfect implementation, Health Econ, vol.19, pp.549-561, 2010. ,

Value of information and pricing new healthcare interventions, Pharmacoeconomics, vol.30, pp.447-459, 2012. ,

Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods, Clin Trial, vol.5, pp.289-300, 2008. ,

The value of information and optimal clinical trial design, Stat Med, vol.24, pp.1791-1806, 2005. ,

Optimal two-stage designs for phase II clinical trials, Control Clin Trials, vol.10, pp.1-10, 1989. ,

Bayesian assessment of sample size for clinical trials of cost-effectiveness, Med Decis Making, vol.21, pp.219-230, 2001. ,

Adaptive designs for subpopulation analysis optimizing utility functions, Biometric J, vol.57, pp.76-89, 2015. ,

Adaptive enrichment designs for clinical trials, Biostatistics, vol.14, pp.613-625, 2013. ,

Adaptive patient enrichment designs in therapeutic trials, Biometric J, vol.51, pp.358-374, 2009. ,

Dose finding by the continual reassessment method, 2011. ,

Application of statistical decision theory to treatment choices: implications for the design and analysis of clinical trials, Stat Med, vol.5, pp.411-420, 1986. ,

ASTIN: A Bayesian adaptive dose-response trial in acute stroke, Clin Trial, vol.2, pp.340-351, 2005. ,

Bandit problems: sequential allocation of experiments, 1985. ,

Multi-armed bandit allocation indices, 1989. ,

Multi-armed bandit allocation indices, 2011. ,

Graphical elicitation of a prior distribution for a clinical trial, J Royal Stat Soc Ser D (The Statistician), vol.42, pp.341-353, 1993. ,

Experiences in elicitation, J Royal Stat Soc: Series D (The Statistician), vol.47, pp.3-19, 1998. ,

Eliciting expert beliefs in substantial practical applications, J Royal Stat Soc: Ser D (The Statistician), vol.47, pp.21-35, 1998. ,

Bayesian methods and ethics in a clinical trial design, pp.159-162, 1996. ,

Structured approach to the elicitation of expert beliefs for a Bayesian-designed clinical trial: a case study, Pharm Stat, vol.12, pp.104-113, 2013. ,

Decision theory: principles and approaches, 2009. ,

Making decisions, 1971. ,

Whether to participate in a clinical trial: The patient's view, pp.267-305, 1996. ,